According to this model, while mutations in MECP2 mainly lead to classic RTT, altered CDKL5 activity would determine, among others, certain phosphorylation-dependent MeCP2 dysfunctions, bringing to a subset of RTT symptoms. This evidence concerns the gene CDKL5 and Rett syndrome.